# American Institute of Mathematical Sciences

• Previous Article
Sampled–data model predictive control: Adaptive time–mesh refinement algorithms and guarantees of stability
• DCDS-B Home
• This Issue
• Next Article
A sufficient optimality condition for delayed state-linear optimal control problems
May  2019, 24(5): 2315-2334. doi: 10.3934/dcdsb.2019097

## Optimal control for a mathematical model for anti-angiogenic treatment with Michaelis-Menten pharmacodynamics

 1 Institute of Mathematics, Lodz University of Technology, 90-924 Lodz, Poland 2 Dept. of Mathematics and Statistics, Southern Illinois University Edwardsville, Edwardsville, Il, 62026-1653, USA 3 Dept. of Electrical and Systems Engineering, Washington University, St. Louis, Mo, 63130, USA

* Corresponding author: Urszula Ledzewicz

Received  January 2018 Revised  January 2019 Published  March 2019

We analyze the structure of optimal protocols for a mathematical model of tumor anti-angiogenic treatment. The control represents the concentration of the agent and we consider the problem to administer an a priori given total amount of agents in order to achieve a minimum tumor volume/maximum tumor reduction. In earlier work, this problem was studied with a log-kill type pharmacodynamic model for drug effects which does not account for saturation of the drug concentration. Here we study the effect of incorporating a Michaelis-Menten (MM) or $E_{\max}$-type pharmacodynamic model, the most commonly used model in the field of pharmacometrics. We compare the formulations of both problems and the resulting solutions. The reformulated problem with $E_{\max}$ pharmacodynamics is no longer linear in the control. This results in qualitative changes in the structure of optimal controls which, in line with an interpretation as concentrations, now are continuous while discontinuities exist if the log-kill model is used which is more in line with an interpretation of the control as dose rates. In spite of these qualitative differences, similarities in the structures of solutions can be observed. Both aspects are discussed theoretically and illustrated numerically.

Citation: Maciej Leszczyński, Urszula Ledzewicz, Heinz Schättler. Optimal control for a mathematical model for anti-angiogenic treatment with Michaelis-Menten pharmacodynamics. Discrete & Continuous Dynamical Systems - B, 2019, 24 (5) : 2315-2334. doi: 10.3934/dcdsb.2019097
##### References:
 [1] B. Bonnard and M. Chyba, Singular Trajectories and their Role in Control Theory, Mathématiques & Applications, vol. 40, Springer Verlag, Paris, 2003. Google Scholar [2] A. Bressan and B. Piccoli, Introduction to the Mathematical Theory of Control, American Institute of Mathematical Sciences, 2007. Google Scholar [3] P. Hahnfeldt, D. Panigrahy, J. Folkman and L. Hlatky, Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Research, 59 (1999), 4770-4775. Google Scholar [4] A. Källén, Computational Pharmacokinetics, Chapman and Hall, CRC, London, 2007.Google Scholar [5] U. Ledzewicz and H. Moore, Dynamical systems properties of a mathematical model for treatment of CML, Applied Sciences, 6 (2016), p291. doi: 10.3390/app6100291. Google Scholar [6] U. Ledzewicz and H. Schättler, The influence of PK/PD on the structure of optimal control in cancer chemotherapy models, Mathematical Biosciences and Engineering (MBE), 2 (2005), 561-578. doi: 10.3934/mbe.2005.2.561. Google Scholar [7] U. Ledzewicz and H. Schättler, Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J. on Control and Optimization, 46 (2007), 1052-1079. doi: 10.1137/060665294. Google Scholar [8] M. Leszczyński, E. Ratajczyk, U. Ledzewicz and H. Schättler, Sufficient conditions for optimality for a mathematical model of drug treatment with pharmacodynamics, Opuscula Math., 37 (2017), 403-419. doi: 10.7494/OpMath.2017.37.3.403. Google Scholar [9] P. Macheras and A. Iliadin, Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics, Interdisciplinary Applied Mathematics, Vol. 30, 2nd ed., Springer, New York, 2016. doi: 10.1007/978-3-319-27598-7. Google Scholar [10] H. Moore, L. Strauss and U. Ledzewicz, Optimization of combination therapy for chronic myeloid leukemia with dosing constraints, J. Mathematical Biology, 77 (2018), 1533-1561. doi: 10.1007/s00285-018-1262-6. Google Scholar [11] A. d'Onofrio and A. Gandolfi, Tumour eradication by antiangiogenic therapy: Analysis and extensions of the model by Hahnfeldt et al. (1999), Mathematical Biosciences, 191 (2004), 159-184. doi: 10.1016/j.mbs.2004.06.003. Google Scholar [12] L. S. Pontryagin, V. G. Boltyanskii, R. V. Gamkrelidze and E. F. Mishchenko, The Mathematical Theory of Optimal Processes, Macmillan, New York, 1964. Google Scholar [13] M. Rowland and T. N. Tozer, Clinical Pharmacokinetics and Pharmacodynamics, Wolters Kluwer Lippicott, Philadelphia, 1995.Google Scholar [14] H. Schättler and U. Ledzewicz, Geometric Optimal Control, Interdisciplinary Applied Mathematics, vol. 38, Springer, 2012. doi: 10.1007/978-1-4614-3834-2. Google Scholar [15] H. Schättler and U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies, Interdisciplinary Applied Mathematics, vol. 42, Springer, 2015. doi: 10.1007/978-1-4939-2972-6. Google Scholar [16] H. E. Skipper, On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future), Bulletin of Mathematical Biology, 48 (1986), 253-278. doi: 10.1007/BF02459681. Google Scholar

show all references

##### References:
 [1] B. Bonnard and M. Chyba, Singular Trajectories and their Role in Control Theory, Mathématiques & Applications, vol. 40, Springer Verlag, Paris, 2003. Google Scholar [2] A. Bressan and B. Piccoli, Introduction to the Mathematical Theory of Control, American Institute of Mathematical Sciences, 2007. Google Scholar [3] P. Hahnfeldt, D. Panigrahy, J. Folkman and L. Hlatky, Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Research, 59 (1999), 4770-4775. Google Scholar [4] A. Källén, Computational Pharmacokinetics, Chapman and Hall, CRC, London, 2007.Google Scholar [5] U. Ledzewicz and H. Moore, Dynamical systems properties of a mathematical model for treatment of CML, Applied Sciences, 6 (2016), p291. doi: 10.3390/app6100291. Google Scholar [6] U. Ledzewicz and H. Schättler, The influence of PK/PD on the structure of optimal control in cancer chemotherapy models, Mathematical Biosciences and Engineering (MBE), 2 (2005), 561-578. doi: 10.3934/mbe.2005.2.561. Google Scholar [7] U. Ledzewicz and H. Schättler, Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J. on Control and Optimization, 46 (2007), 1052-1079. doi: 10.1137/060665294. Google Scholar [8] M. Leszczyński, E. Ratajczyk, U. Ledzewicz and H. Schättler, Sufficient conditions for optimality for a mathematical model of drug treatment with pharmacodynamics, Opuscula Math., 37 (2017), 403-419. doi: 10.7494/OpMath.2017.37.3.403. Google Scholar [9] P. Macheras and A. Iliadin, Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics, Interdisciplinary Applied Mathematics, Vol. 30, 2nd ed., Springer, New York, 2016. doi: 10.1007/978-3-319-27598-7. Google Scholar [10] H. Moore, L. Strauss and U. Ledzewicz, Optimization of combination therapy for chronic myeloid leukemia with dosing constraints, J. Mathematical Biology, 77 (2018), 1533-1561. doi: 10.1007/s00285-018-1262-6. Google Scholar [11] A. d'Onofrio and A. Gandolfi, Tumour eradication by antiangiogenic therapy: Analysis and extensions of the model by Hahnfeldt et al. (1999), Mathematical Biosciences, 191 (2004), 159-184. doi: 10.1016/j.mbs.2004.06.003. Google Scholar [12] L. S. Pontryagin, V. G. Boltyanskii, R. V. Gamkrelidze and E. F. Mishchenko, The Mathematical Theory of Optimal Processes, Macmillan, New York, 1964. Google Scholar [13] M. Rowland and T. N. Tozer, Clinical Pharmacokinetics and Pharmacodynamics, Wolters Kluwer Lippicott, Philadelphia, 1995.Google Scholar [14] H. Schättler and U. Ledzewicz, Geometric Optimal Control, Interdisciplinary Applied Mathematics, vol. 38, Springer, 2012. doi: 10.1007/978-1-4614-3834-2. Google Scholar [15] H. Schättler and U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies, Interdisciplinary Applied Mathematics, vol. 42, Springer, 2015. doi: 10.1007/978-1-4939-2972-6. Google Scholar [16] H. E. Skipper, On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future), Bulletin of Mathematical Biology, 48 (1986), 253-278. doi: 10.1007/BF02459681. Google Scholar
$E_{\max}$ pharmacodynamic model.
Geometric shape of the sets ${\mathcal L}_0$ and ${\mathcal L}_m$ and definition of the associated regions $R_i$ and $S_i$ for ${i}{\rm{ = 1, 2, 3, 4}}{\rm{.}}$
The region $S_2$ (inside the loop ${\mathcal L}_m$ and above the diagonal) is not positively invariant for $u = u_{\max}$.
Graph of the value $V(\varepsilon)$ for the one-parameter family ${\mathcal F}_{\varepsilon}$ near its minimum value.
Optimal control (left) and corresponding trajectory (right) for the initial condition $(p_0, q_0) = (4600, 5800)$ and $A = 12$. The graphs are shown with $UC_{50} = 50$, $U_{\max} = 1.5UC_{50} = 75$ and $A = 12UC_{50} = 600$. The optimal controlled trajectory crosses the diagonal along a full dose segment and the optimal concatenation sequence is full dose $\rightarrow$ $\tilde{u}$ $\rightarrow$ no dose. The initial full dose segment is shown in black, the intermediate interior control segment in blue and the final no dose segment in black; junctions are marked with an asterisk. The loop ${\mathcal L}_m$ is shown as the dashed red curve.
Optimal control (left) and corresponding trajectory (right) for the initial condition $(p_0, q_0) = (12000, 15000)$ and $A = 2$. The graphs are shown with $UC_{50} = 50$, $U_{\max} = 1.5UC_{50} = 75$ and $A = 2UC_{50} = 100$. The optimal controlled trajectory crosses the diagonal using intermediate doses along the control $\tilde{u}$ and the optimal concatenation sequence is of the shortened form $\tilde{u}$ $\rightarrow$ no dose. The optimal controlled trajectory is shown in red and as a comparison the corresponding full dose trajectory is shown in blue. Here there is a significant difference in the final tumor volumes.
Parameter values used in numerical computations.
 variable/coefficients interpretation numerical value dimension $p$ tumor volume $mm^{3}$ $q$ carrying capacity of the vasculature $mm^{3}$ $\xi$ tumor growth parameter $0.192$ per day $\mu$ natural loss of endothelial support $0.02$ per day $b$ stimulation parameter, 'birth' $5.85$ per day $d$ inhibition parameter, 'death' $0.00873$ $mm^{-2}$ per day $G$ anti-angiogenic killing coefficient at limiting concentration $10$ per day $UC_{50}$ concentration with 50% effect $1$ $u_{\max}$ normalized maximum dose rate $1.5$ $A$ normalized total dose $2$; $12$
 variable/coefficients interpretation numerical value dimension $p$ tumor volume $mm^{3}$ $q$ carrying capacity of the vasculature $mm^{3}$ $\xi$ tumor growth parameter $0.192$ per day $\mu$ natural loss of endothelial support $0.02$ per day $b$ stimulation parameter, 'birth' $5.85$ per day $d$ inhibition parameter, 'death' $0.00873$ $mm^{-2}$ per day $G$ anti-angiogenic killing coefficient at limiting concentration $10$ per day $UC_{50}$ concentration with 50% effect $1$ $u_{\max}$ normalized maximum dose rate $1.5$ $A$ normalized total dose $2$; $12$
 [1] Urszula Ledzewicz, Helen Moore. Optimal control applied to a generalized Michaelis-Menten model of CML therapy. Discrete & Continuous Dynamical Systems - B, 2018, 23 (1) : 331-346. doi: 10.3934/dcdsb.2018022 [2] Filippo Cacace, Valerio Cusimano, Alfredo Germani, Pasquale Palumbo, Federico Papa. Closed-loop control of tumor growth by means of anti-angiogenic administration. Mathematical Biosciences & Engineering, 2018, 15 (4) : 827-839. doi: 10.3934/mbe.2018037 [3] Karl Peter Hadeler. Michaelis-Menten kinetics, the operator-repressor system, and least squares approaches. Mathematical Biosciences & Engineering, 2013, 10 (5&6) : 1541-1560. doi: 10.3934/mbe.2013.10.1541 [4] Shuo Wang, Heinz Schättler. Optimal control for cancer chemotherapy under tumor heterogeneity with Michealis-Menten pharmacodynamics. Discrete & Continuous Dynamical Systems - B, 2019, 24 (5) : 2383-2405. doi: 10.3934/dcdsb.2019100 [5] Manuel Delgado, Cristian Morales-Rodrigo, Antonio Suárez. Anti-angiogenic therapy based on the binding to receptors. Discrete & Continuous Dynamical Systems - A, 2012, 32 (11) : 3871-3894. doi: 10.3934/dcds.2012.32.3871 [6] Jagadeesh R. Sonnad, Chetan T. Goudar. Solution of the Michaelis-Menten equation using the decomposition method. Mathematical Biosciences & Engineering, 2009, 6 (1) : 173-188. doi: 10.3934/mbe.2009.6.173 [7] Ellina Grigorieva, Evgenii Khailov, Andrei Korobeinikov. An optimal control problem in HIV treatment. Conference Publications, 2013, 2013 (special) : 311-322. doi: 10.3934/proc.2013.2013.311 [8] Maria do Rosário de Pinho, Helmut Maurer, Hasnaa Zidani. Optimal control of normalized SIMR models with vaccination and treatment. Discrete & Continuous Dynamical Systems - B, 2018, 23 (1) : 79-99. doi: 10.3934/dcdsb.2018006 [9] Joaquim P. Mateus, Paulo Rebelo, Silvério Rosa, César M. Silva, Delfim F. M. Torres. Optimal control of non-autonomous SEIRS models with vaccination and treatment. Discrete & Continuous Dynamical Systems - S, 2018, 11 (6) : 1179-1199. doi: 10.3934/dcdss.2018067 [10] Cristiana J. Silva, Delfim F. M. Torres. A TB-HIV/AIDS coinfection model and optimal control treatment. Discrete & Continuous Dynamical Systems - A, 2015, 35 (9) : 4639-4663. doi: 10.3934/dcds.2015.35.4639 [11] Urszula Ledzewicz, Mohammad Naghnaeian, Heinz Schättler. Dynamics of tumor-immune interaction under treatment as an optimal control problem. Conference Publications, 2011, 2011 (Special) : 971-980. doi: 10.3934/proc.2011.2011.971 [12] Yali Yang, Sanyi Tang, Xiaohong Ren, Huiwen Zhao, Chenping Guo. Global stability and optimal control for a tuberculosis model with vaccination and treatment. Discrete & Continuous Dynamical Systems - B, 2016, 21 (3) : 1009-1022. doi: 10.3934/dcdsb.2016.21.1009 [13] Cristiana J. Silva, Delfim F. M. Torres. Optimal control strategies for tuberculosis treatment: A case study in Angola. Numerical Algebra, Control & Optimization, 2012, 2 (3) : 601-617. doi: 10.3934/naco.2012.2.601 [14] Sanjukta Hota, Folashade Agusto, Hem Raj Joshi, Suzanne Lenhart. Optimal control and stability analysis of an epidemic model with education campaign and treatment. Conference Publications, 2015, 2015 (special) : 621-634. doi: 10.3934/proc.2015.0621 [15] Djamila Moulay, M. A. Aziz-Alaoui, Hee-Dae Kwon. Optimal control of chikungunya disease: Larvae reduction, treatment and prevention. Mathematical Biosciences & Engineering, 2012, 9 (2) : 369-392. doi: 10.3934/mbe.2012.9.369 [16] Holly Gaff, Elsa Schaefer. Optimal control applied to vaccination and treatment strategies for various epidemiological models. Mathematical Biosciences & Engineering, 2009, 6 (3) : 469-492. doi: 10.3934/mbe.2009.6.469 [17] Kbenesh Blayneh, Yanzhao Cao, Hee-Dae Kwon. Optimal control of vector-borne diseases: Treatment and prevention. Discrete & Continuous Dynamical Systems - B, 2009, 11 (3) : 587-611. doi: 10.3934/dcdsb.2009.11.587 [18] M. Delgado-Téllez, Alberto Ibort. On the geometry and topology of singular optimal control problems and their solutions. Conference Publications, 2003, 2003 (Special) : 223-233. doi: 10.3934/proc.2003.2003.223 [19] Shihchung Chiang. Numerical optimal unbounded control with a singular integro-differential equation as a constraint. Conference Publications, 2013, 2013 (special) : 129-137. doi: 10.3934/proc.2013.2013.129 [20] Térence Bayen, Marc Mazade, Francis Mairet. Analysis of an optimal control problem connected to bioprocesses involving a saturated singular arc. Discrete & Continuous Dynamical Systems - B, 2015, 20 (1) : 39-58. doi: 10.3934/dcdsb.2015.20.39

2018 Impact Factor: 1.008